Gábor Somlyai graduated as a biologist from the University of Szeged in 1982. Between 1982 and 1990 he worked for the Department of Plant Pathology, Plant Protection Institute of the Hungarian Academy of Sciences. He had a scholarship from the Hungarian Academy of Sciences while studying for his PhD and defended his thesis in molecular biology in 1988. Dr. Somlyai spent six months at the Georg-August University in Göttingen on a DFG scholarship after receiving his PhD. He followed that with a postdoctoral fellowship in the field of genetic engineering and gene mapping at the University of Missouri in Columbia, Missouri.
In the wake of the Hungarian Nobel-prize winning scientist Albert Szent-Györgyi – who said that the true cause of cancer should be looked for at the sub-molecular level – Gábor began his examining the biological importance of naturally occurring deuterium as a senior research fellow at the Hungarian Institute of Oncology in 1990.
In 1993 Gabor established HYD Ltd. for Research and Development (now HYD LLC. for Cancer Research and Drug Development) to carry out cancer research and drug development based on the proprietary procedure called deuterium depletion. Dr. Somlyai served as the scientific director of HYD Ltd. between 1993 and 1997 before beoming the CEO of the company. In 2012 he also began serving as the General Director of HYD’s parent company, HYD Pharma Inc.
His book, Defeating Cancer!, was published in Hungary in 2000. It has since been published in Romania, Japan, China, South-Korea and the U.S.A.
Gábor is a holder of numerous international patents, an author of more than 40 scientific publications, and is a highly sought-after speaker at international conferences.